ArticleAPL bioengineering2025
Analysis of immune cell infiltration landscape and identification of diagnostic biomarkers in ankylosing spondylitis.
Article in APL bioengineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ankylosing spondylitis (AS), characterized by inflammation of sacroiliac joints and spinal attachments, has an unclear pathogenesis. This study aims to screen and authenticate immune cell-associated biomarkers in AS. Two Gene Expression Omnibus datasets (GSE25101 and GSE41038) were combined as the discovery dataset, with candidate biomarkers screened via differential expression analysis, immune cell infiltration analysis, and weighted gene co-expression network analysis (WGCNA). Immune cell-related biomarkers were further identified and validated by receiver operating characteristic (ROC) analysis using the confirmatory dataset GSE73754, and potential diagnostic biomarkers were finally confirmed by reverse transcription quantitative polymerase chain reaction (RT-qPCR), immunofluorescence staining, and single-cell RNA sequencing (scRNA-seq) analysis (GSE194315). Thirty-two differentially expressed genes between the AS and control samples were identified. The ratio of M2 macrophages was significantly different between the AS and control samples. Seven candidate biomarkers associated with immune cells in AS were identified by WGCNA and Venn diagram. Then, three genes (SBK1, HNRPR, and CX3CR1) were authenticated as immune cell-associated biomarkers in AS by ROC curves, indicating a possible diagnostic value in clinical settings. The results of RT-qPCR, immunofluorescence staining, and scRNA-seq analysis all confirmed that CX3CR1 was down-regulated in AS, which was in line with bioinformatics study findings. Dysregulation of the CX3CR1 and M2-type macrophage ratio are key factors in AS, which lay the groundwork for exploring illness pathophysiology and yielding fresh perspectives on AS diagnosis and therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.